KL A289
Alternative Names: A-289; KL-A289Latest Information Update: 11 Jul 2022
At a glance
- Originator Klus Pharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 11 Jul 2022 Phase-I clinical trials in Solid tumours in China (Parenteral) (Klus Pharma pipeline, July 2022)
- 11 Jul 2022 Klus Pharma plans clinical trial in Solid tumours (Combination therapy) (Parenteral) (Klus Pharma pipeline, July 2022)
- 08 Sep 2021 KL A289 is available for licensing as of 31 Aug 2020. https://www.kluspharma.com/pipeline